From Data to Practice: Crafting Effective Clinical Protocols and Partnerships for Gastroparesis Management
This video includes a discussion on the emerging clinical evidence on gastroparesis, best practices and criteria for patient selection, and the benefits of a multi-disciplinary management approach.
Camille Thélin
M.D., M.Sc.
Associate Professor & Fellowship Director
USF Gastroenterology
Director, USF Women’s Digestive Health
Co-Director/Founder, USF
Neurogastromotility Clinic
Bailey Blankenship
MSN, APRN, FNP-C
Neurogastromotility Nurse Practitioner
University of South Florida
IMPORTANT SAFETY INFORMATION
Enterra Therapy for treatment of chronic, resistant to medication nausea and vomiting associated with gastroparesis caused by diabetes or an unknown origin in patients aged 18 to 70 years: patients should always discuss potential risks and benefits of the device with their physician.
HUMANITARIAN DEVICE
Authorized by Federal law for use in the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years. The effectiveness of this device for this use has not been demonstrated. What does this mean?